Abstract
Every tumor microenvironment, consequential biological barriers naturally embattle for nanotherapeutics penetration. Disintegrating those obstacles, finding a narrow physiochemical slit with the eye-opening prospect in the way of extravasation or penetration of nanoplatform sounds inevitable. For this reason, our tools comprised of the incorporation of multiple modalities as well as bio-, chemo-functionalization which prompt graphene-based material to release drug, at tumor site adequately with the matching features of these barriers. Those obstacles are being brought with relevant discussions and at rest effective and innovative stimuli design against them have been disputed. Although there has not been reported one regitration of graphene-based material clinical application in terms of drug delivery application; graphene-related reports just have been hampered at the preclinical animal level. This review glimpses the mechanism of cellular internalization of graphene-based material and harnesses its inherent physicochemical properties through current stimuli-responsive strategies. Overall, issues covered here deal with the mechanism of internalization, stimuli, nano-therapeutics release mechanism, a consequence of increased ionic strength, phenomena of synergistic electro-osmosis, cataphoresis; π − π interaction role, drug's aromatic part contribution, H-bond, Van der Waals force, steric hindrance, electrostatic features, and relevant in-silico calculation outcomes. In this review, graphene-based material drug delivery systems struggling against tumor microenvironment complications and already have been fragmented to realize how microenvironment-based strategies promoted nanotherapeutics penetration through biological barriers. The latest finding on chemical progress in terms of chirality and biodegradability in conjugation with advanced emerging technologies in drug screening have been drawn-out within the probable prospects paradigm.
| Originalsprog | Engelsk |
|---|---|
| Artikelnummer | 100381 |
| Tidsskrift | FlatChem |
| Vol/bind | 34 |
| DOI | |
| Status | Udgivet - jul. 2022 |
Bibliografisk note
Funding Information:The authors express thank to the anonymous members for their attitudes, and constructive collaborations. as well as the authors acknowledge Rio de Janeiro State University (UERJ) especially neurophysiology group (IBRAG) and also Iran University of Science and Technology (IUST). Graphene (G); Graphene-based material (GBM); Graphene Quantum Dots (GQDs); Reduced GO (rGO); Magnetic GO (MGO); Pristine Graphene (PG); Graphene Oxide (GO); Drug delivery (DD); Enhanced Permeability and Retention (EPR); Red Blood Cells (RBCs); mononuclear phagocyte system (MPS); Interstitial Fluid Pressures (IFP); Extracellular Matrix (ECM); Indocyanine Green (ICG); Amine Modified-GQDs (AG-QDs), Lower Critical Solution Temperature (LCST); Upper Critical Solution Temperature (UCST); Cyclooxygenase (COX); Chlorogenic Acid (CA); Hyaluronic Acid-Chitosan-g-Poly (N-isopropylacrylamide) (HACPN); Hydroxyethyl Cellulose (HEC); Poly (lactic-co-glycolic acid) (PLGA); Gum Tragacanth (GT); Chitosan (CS); Near-infrared (NIR); Ultrasound (US); Folic Acid (FA); Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL); 5-Fluorouracil (FU); Vancomycin (VAN); Adriamycin (ADR); Camptothecin (CPT); Chlorhexidine (CHX); Doxorubicin (DOX); docetaxel (DTX); Quercetin (Qu); Ciprofloxacin (CIP); Curcumin (CUR); Paclitaxel (PTX); Irinotecan (CPT-11); Rivastigmine (RIV); Methotrexate (MTX); Elsinochrome A (EA); Diclofenac Sodium (DS); glutathione (GSH); Reactive Oxygen Species (ROS), Adenosine-5′-triphosphate (ATP); Molecular dynamics simulation (MDs); Theory of Atoms in Molecules (AIM); Density Functional Theory (DFT); Hydrogen Bond (H-bond); Van der Waals (Vdw); Poly acrylic acid (PAA); Dexamethasone (DEX); Cephalexin (CPL); Indomethacin (IMC); Phenanthroline (p-HPIP); Arginine-glycine-aspartic acid peptide (RGD); Polyethylene glycol (PEG); Food and Drug Administration (FDA); Tumor Microenvironment (TME).
Publisher Copyright:
© 2022 Elsevier B.V.